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Abstract
Naturally occurring diabetes mellitus (DM) is common in domestic cats (Felis catus). It has
been proposed as a model for human Type 2 DM given many shared features. Small case
studies demonstrate feline DM also occurs as a result of insulin resistance due to a somato-
trophinoma. The current study estimates the prevalence of hypersomatotropism or acro-
megaly in the largest cohort of diabetic cats to date, evaluates clinical presentation and
ease of recognition. Diabetic cats were screened for hypersomatotropism using serum total
insulin-like growth factor-1 (IGF-1; radioimmunoassay), followed by further evaluation of a
subset of cases with suggestive IGF-1 (>1000 ng/ml) through pituitary imaging and/ or histo-
pathology. Clinicians indicated pre-test suspicion for hypersomatotropism. In total 1221 dia-
betic cats were screened; 319 (26.1%) demonstrated a serum IGF-1>1000 ng/ml (95%
confidence interval: 23.6–28.6%). Of these cats a subset of 63 (20%) underwent pituitary
imaging and 56/63 (89%) had a pituitary tumour on computed tomography; an additional
three on magnetic resonance imaging and one on necropsy. These data suggest a positive
predictive value of serum IGF-1 for hypersomatotropism of 95% (95% confidence interval:
90–100%), thus suggesting the overall hypersomatotropism prevalence among UK diabetic
cats to be 24.8% (95% confidence interval: 21.2–28.6%). Only 24% of clinicians indicated a
strong pre-test suspicion; most hypersomatotropism cats did not display typical phenotypi-
cal acromegaly signs. The current data suggest hypersomatotropism screening should be
considered when studying diabetic cats and opportunities exist for comparative acromegaly
research, especially in light of the many detected communalities with the human disease.
Introduction
Spontaneous diabetes mellitus (DM) in the domestic cat (Felis catus) is currently estimated to
affect approximately 1 in 200 household cats in the UK [1] and between 1 and one and a half in
PLOSONE | DOI:10.1371/journal.pone.0127794 May 29, 2015 1 / 18
OPEN ACCESS
Citation: Niessen SJM, Forcada Y, Mantis P, Lamb
CR, Harrington N, Fowkes R, et al. (2015) Studying
Cat (Felis catus) Diabetes: Beware of the
Acromegalic Imposter. PLoS ONE 10(5): e0127794.
doi:10.1371/journal.pone.0127794
Academic Editor: Andrew Wolfe, John Hopkins
University School of Medicine, UNITED STATES
Received: February 4, 2015
Accepted: April 19, 2015
Published: May 29, 2015
Copyright: © 2015 Niessen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: There were no funders involved with this
project. Therefore funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
200 household cats in Australia [2]. This number, in concordance with human DM, is rapidly
rising. For example, in the United States estimates rose from less than a half per 200 in 1970 to
approximately two and a half in 200 in 1999 [3]. In addition to therefore being an important
endocrinopathy in veterinary medicine, feline DM has been increasingly studied in the field of
comparative endocrinology as a spontaneous model for human type 2 DM based on a multi-
tude of shared characteristics. Indeed, domestic cats share the same environment as their
human counterparts and, akin to the situation in man, the diabetic cat seems to suffer from a
combination of insulin resistance and beta-cell dysfunction [4–6]. Additionally, like in hu-
mans, diabetic cats generally are middle-aged at time of diagnosis and both obesity and inactiv-
ity pose significant risk factors for its development [1,4,5]. Furthermore, similarities exist in the
genetic predisposition for human type 2 DM and feline DM. Polymorphisms in the melanocor-
tin receptor 4 gene are associated with DM in both overweight cats and humans [7]. Finally,
man and cat share histopathological features of Type 2 DM with deposition of pancreatic islet
amyloid being demonstrable in both species [5,8–10].
However, although this feline type 2 DM is suspected to be the most common type of spon-
taneous DM in the cat, other types of spontaneous feline DM have also been described to
occur, particularly DM as a consequence of endogenous overproduction of hormones with an
insulin-antagonistic effect such as cortisol (hyperadrenocorticism or Cushing’s syndrome) and
growth hormone (HS or acromegaly) [11]. Relatively small case series have described HS in
cats and to date, only one small scale pilot screening study has been performed, which in fact
hinted towards HS-induced DM to be unexpectedly common among diabetic cats, with 59 out
of 184 diabetic cats (32%) showing evidence of the disease [12]. Data on pre-test clinical suspi-
cion for HS were not included in this small study. Interestingly, all reported feline acromegalics
have been diabetic, in contrast to the situation in man, where acromegaly induces DM only in a
proportion of patients [11,13,14].
Confirmation of a high prevalence of this different type of DM among a larger cohort of dia-
betic cats would have a considerable impact on the use of feline DM in comparative endocri-
nology research, the overall understanding of feline DM and the approach of the veterinary
profession to its management. This impact would be even greater, if the feline syndrome
proved difficult to recognise phenotypically and therefore would be missed without routine
laboratory screening. Finally, a high prevalence of feline acromegaly would mean attractive op-
portunities exist for comparative somatotrophinoma research.
In light of the initial pilot data [12], a complete study seemed warranted and, therefore, the
current study aimed to quantify the true potential relative contribution of naturally occurring
HS in the etiology of spontaneous feline diabetes mellitus through the screening of the largest
cohort of diabetic pet cats ever reported. In order to further investigate the need for routine HS
screening of diabetic cats, the study also aimed to assess pre-test suspicion among veterinary
professionals, as well as to compare clinical features of diabetic acromegalic and diabetic non-
acromegalic cats.
Materials and Methods
Recruitment of diabetic cats
Serum fructosamine concentration is a reflection of average level of glycaemia over the preced-
ing two to three weeks in cats and is currently routinely used by veterinarians in the diagnosis
of DM and the subsequent evaluation of glycaemic control after the start of insulin treatment.
From October 2003 till April 2011 evaluation of serum fructosamine was offered free of charge
for all diabetic cats attending any veterinary practice in the UK. This service was widely and
continuously advertised to the veterinary profession around the UK through multiple channels
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of communication (websites, newsletters, regional and national conference presentations).
Cats were defined as diabetic on the basis of documentation of clinical signs suggestive of dia-
betes mellitus and persistent elevation of fasted blood glucose concentrations. At the time of
sample submission, attending veterinarians were asked to record clinical data about the patient,
including age, breed, gender, current body weight, current administered insulin dose (consid-
ered part of standard treatment for feline DM) and whether they clinically suspected acromeg-
aly/ hypersomatotropism. The latter suspicion was categorized into 3 options (1. Yes, strongly;
2. No; 3. Maybe). Excess serum was used to evaluate basal total IGF-1 concentration in all re-
ceived diabetic cat samples.
Diagnosis of hypersomatotropism
Diabetic cats were classified as suspected HS-induced DM on the basis of elevation of serum
basal total IGF-1 concentration above 1000 ng/ml. At this cut-off serum IGF-1 was previously
shown to have a positive predictive value of 95% for the presence of HS in the diabetic cat
[11,12]. All veterinarians dealing with a cat with a serum IGF-1 concentration that exceeded
1000 ng/mL, were sent a standard letter explaining the cat could be suffering from hypersoma-
totropism and inviting the owner to attend a dedicated Veterinary Endocrinology Clinic run
by board-certified veterinary internists to have pituitary computed tomography (CT) (Mx8000
IDT, Philips, Best, The Netherlands) performed on their cat(free of charge). During the last
two years of this surveillance study, these invitations were also sent to all veterinarians taking
care of cats of which the IGF-1 concentration proved between 500 and 1000 ng/ml. All CT
scans were performed with the cat in sternal recumbency under deep sedation (intravenous
midazolam and ketamine). Images were acquired before and immediately after administration
of an intravenous bolus 2 mL/kg of iohexol (Omnipaque 300mgI/mL GE Healthcare, Norway).
In CT images, the dorsal and lateral aspects of the pituitary were considered to be the interface
between contrast-enhanced tissue occupying the pituitary fossa and the midbrain in images
with a soft tissue window (width 200, level 80). The ventral aspect of the pituitary was consid-
ered to be in contact with the dorsal aspect of the basisphenoid bone forming the pituitary
fossa, which was identified in images with a bone window (width 2500, level 500). Diagnosis of
pituitary enlargement was based on observing a dorsoventral dimension of the pituitary
>4.0mm and/or transverse dimension>6.0mm [15]. If the CT proved unremarkable, pituitary
magnetic resonance imaging (MRI) (1.5T Intera Pulsar System, Philips Medical Systems, Rei-
gate, UK) was subsequently offered to the owners of the cat. All MR studies were done with
cats in dorsal recumbency under general anesthesia (propofol induction and isoflurane mainte-
nance). Spin-echo T1-weighted images were acquired before and immediately after administra-
tion of an intravenous bolus of 0.1mmol/kg gadoterate meglumine (Dotarem, Guerbet, Milton
Keynes, UK). CT and MR images were evaluated by a board-certified veterinary radiologist.
Necropsy permission was requested at time of death and performed by a board-certified veteri-
nary pathologist if granted. Based on current consensus in veterinary endocrinology, diabetic
cats were classified as confirmed HS-induced DM on the basis of recording significant eleva-
tion of serum basal total IGF-1 concentration (>1000 ng/ml) and an enlargement of the pitui-
tary on pituitary imaging (CT or MRI) or a structural pituitary abnormality on necropsy [16].
Clinical signs shown by confirmed acromegalic cats were compared with those shown by 20
randomly chosen cats presented with newly diagnosed primary diabetes mellitus (HS deemed
unlikely based on a normal serum IGF-1 concentration) at the same Veterinary Endocrinology
Clinic. This study was approved by the Royal Veterinary College’s Ethical Committee and all
procedures were performed as part of the routine veterinary care of the individual animal
under the Veterinary Surgeons Act applicable in the United Kingdom. The data reported in
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this study include the data reported in the initial pilot screening study (184 diabetic cats of
which 59 with an IGF-1> 1000 ng/ml) [12] given that the current study represents an exten-
sion of that pilot study (using the same methodology) and in order to preserve the integrity of
the data-set.
Pituitary enlargement prevalence in middle-aged and older cats
In order to estimate the prevalence of pituitary enlargements unlikely related to hypersomato-
tropism, a board-certified veterinary radiologist (CL) analysed the pituitary size in 62 consecu-
tive CT studies of middle-aged and older cats that presented to our veterinary hospital for
imaging of the head, though explicitly not the brain (e.g. cats presenting for chronic rhinitis,
otitis, jaw trauma). As per above, diagnosis of pituitary enlargement was based on observing a
dorsoventral dimension of the pituitary>4.0mm and/or transverse dimension>6.0mm [15].
Assays
All blood samples were collected via venipuncture into serum gel tubes after a minimum of 6
hours fasting and prior to exogenous insulin administration. Samples arrived at the laboratory
within 24 hours of collection. Fructosamine was measured via colorimetric assay, based on the
ability of ketoamines to reduce nitrotetrazolium blue to formazans in an alkaline medium and
a reference interval was previously established (reference interval, 205–322 μmol/L). Basal total
serum IGF-1 was measured using a radioimmunoassay system (RIA) which employs a human
anti-IGF-1 antibody and is currently most commonly used for the diagnosis of HS in the cat
(positive predictive value of 95% at a cut-off value of 1000 ng/mL) [12,17]. The fructosamine
and IGF-1 assays were not changed during the entire evaluation period and consistency of
both assays proven by ongoing intra- and inter-assay coefficient of variation (CV) surveillance
(fructosamine: inter-assay CV 3.22% for a standard sample of 274 μmol/l; 3.47% for a standard
sample of 557 μmol/l; intra-assay CV 1.27% for a cat sample of 204 μmol/l run 25 times; 0.96%
for a cat sample of 565 μmol/l run 18 times; IGF-1: inter-assay CV 4.6% for a cat sample of
519 ng/ml; 9.3% for a standard sample of 216 ng/ml; 12.1% for a standard sample of 62 ng/ml;
intra-assay CV 7.9% for a cat sample of 172 ng/ml run 18 times). Cross-reactivity of the IGF-1
assay with exogenous insulin was tested by spiking cat serum samples with a range of concen-
trations of the three exogenous insulin types used in the studied population (insulin lente, prot-
amine zinc insulin and insulin glargine); cross-reactivity was not apparent.
Statistical evaluation
Prevalence data are presented with 95% confidence intervals (CI) where appropriate. Depend-
ing on the presence of normal distribution, continuous parameters (e.g. fructosamine concen-
trations, body weight, insulin requirements, age) were compared by Student’s t-test or Mann-
Whitney U-test respectively. The proportions of categorical data (affected breeds, gender:
male/female entire, male/female neutered, clinical signs) were compared using a Chi-square
(comparison of the large number of cats with IGF-1> and< 1000 ng/ml in the overall
screened population) or Fischer’s Exact test (comparison of the smaller number of confirmed
acromegalic cats with regular diabetic cats). Correlations between IGF-1 and body weight were
assessed by calculating a Spearman’s rho; correlation between duration of exogenous insulin
administration (days) and IGF-1 by calculating Pearson’s coefficient of correlation Calcula-
tions were performed using commercial software (Statistical Package for the Social Sciences,
SPSS, version 16, IBM, Portsmouth, UK and Excel, Microsoft, Redmond, USA). The signifi-
cance level used in the current studies was P<0.05, unless multiple testing took place, in which
case additional post hoc Bonferroni correction was applied.
Hypersomatotropism-Induced Diabetes Mellitus in the Cat
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Results
Proportion of suspected hypersomatotropism-induced DM in the diabetic
cat population
Over the 9-year-period 1221 diabetic cat samples were received by the laboratory for the pur-
pose of fructosamine evaluation; these include the 184 cat samples initially evaluated in the
pilot study [12]. Three hundred and nineteen samples (26.1%) demonstrated serum total IGF-
1 concentrations higher than 1000 ng/ml (95% CI: 23.6–28.6%); the remaining samples with
an IGF-1< 1000 ng/ml had a mean+/-SD IGF-1 concentration of 468+/-221 ng/ml. A compar-
ison of characteristics between diabetic cats with high and low IGF-1 concentration (cut-off
1000 ng/ml) is shown in Table 1, depicting age, breed, gender, body weight, fructosamine con-
centration, exogenous insulin dose and percentage of submitting clinicians suspecting HS on
the basis of clinical picture at time of sample submission. Half (50%) of the clinicians examin-
ing the cats with IGF-1< 1000 ng/ml did not suspect presence of HS (answering ‘no’), whereas
a quarter (24%) of clinicians examining the cats with IGF-1>1000ng/ml strongly suspected
presence of HS; the remainder was non-committal (answering ‘maybe’). The mean+/-SD dura-
tion of exogenous insulin administration in both groups was not significantly different (IGF-
1<1000 ng/ml: 146+/-215 days;>1000: 133+/-200 days; P = 0.49; t-test). Additionally, there
was only a very weak significant correlation between serum IGF-1 and duration of insulin ad-
ministration in the<1000 ng/ml group (Pearson’s correlation coefficient: 0.0859, P = 0.0099);
and no significant correlation in the>1000 ng/ml group (Pearson’s correlation coefficient:
0.000152; P = 1.0).
Diabetic cats with IGF-1 greater than 1000 ng/ml demonstrated a higher body weight
(MannWhitney test, p = 0.015), lower age (MannWhitney test, p = 0.03), higher fructosamine
concentration (MannWhitney test, p<0.001), as well as higher administered insulin dose per
Table 1. Table comparing basic characteristics of diabetic cats with excessively high (>1000ng/ml) and low (<1000 ng/ml) serum total insulin-like
growth factor-1 (IGF-1) concentration.
Number Age
(years,
mean
+/-SD
Breed Gender Body
weight
(kg)
Fructosamine
(μmol/l, mean
+/-SD)
Insulin
dose (iu/
day, mean
+/-SD)
Clinicians
suspecting HS
(%)
IGF-
1<1000
ng/ml
902
(73.9%)
11.8+/-3.2 747 DSHa (83%), 82 DLHb
(9%), 22 Burmese (2%), 7
Abyssinian (0.8%), 5 Maine
Coon (0.6%), 5 Siamese
(0.6%), 3 Persian (0.3%), 2
Bengal (0.2%), 2 British Blue
(0.2%), 2 Russian Blue (0.2%),
10 other breeds (1%)
588 MNd (65%)
14 MEe(1.6%)
290 FNf (32%)7
FEg(0.8%)
5.2+/-1.4 476+/-152 5.8+/-5 No: 450 (50%)
Maybe: 179
(20%)Yes: 10
(1%)
IGF-
1>1000
ng/ml
319
(26.1%)
11.3+/-2.7 271 DSH (85%), 22 DLH (7%),
5 Burmese (2%), 5 Maine
Coon (1.6%), 2 BSHc (0.6%)
226 MNd (71%)8
MEe (2.5%)82
FNf (26%)2 FEg
(0.6%)
5.4+/-1.3 560+/-142 13.8+/-10 No: 47 (15%)
Maybe: 127
(40%)Yes: 78
(24%)
aDomestic Short Hair Cat
bDomestic Long Hair Cat
cBritish Short Hair Cat
dmale neutered
emale entire
ffemale neutered
gfemale entire.
doi:10.1371/journal.pone.0127794.t001
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day (MannWhitney test, p<0.001), though only the latter two features proved significant after
post hoc Bonferroni correction. Although proportionately three times as many Maine Coon
cats were represented in the IGF-1>1000 ng/ml group, cat breed distribution did not prove sig-
nificantly different between the two groups (Chi-square, p = 0.23), nor did gender distribution
(Chi-square, p = 0.13). In diabetic cats with IGF-1<1000 ng/ml, a small but significant correla-
tion existed between body weight and IGF-1 concentration (Spearman’s rho 0.34, p<0.001),
which did not exist in those with IGF-1>1000 ng/ml (Spearman’s rho -0.07, p = 0.294).
Confirmation of hypersomatotropism-induced DM
Sixty-three of 319 diabetic cats (20%) from the suspected HS-induced DM category were avail-
able for a visit to the Veterinary Endocrinology Clinic and subsequent intracranial imaging.
Fifty-six of these 63 cats (89%) had a demonstrable pituitary lesion on CT imaging (Fig 1). Out
of the seven cats that did not show such lesion, five subsequently underwent intra-cranial MR
imaging, which demonstrated a lesion in the pituitary in three cats, additionally confirming
presence of HS in these cases. Of the two cats with no lesion on CT or MR imaging, one under-
went necropsy which demonstrated acidophilic hyperplasia (this cat formed part of the pilot
study [12]). Altogether 60 of the 63 assessed cases were confirmed to have HS. The positive
predictive value of the employed IGF-1 RIA for the diagnosis of HS in the cat at a cut-off of
1000 ng/ml was therefore calculated to be 95% (95% CI: 90–100%). A systematic overview of
Fig 1. Protrusion of the pituitary beyond the dorsal rim of the sella turcica. This figure shows an
example of a transverse, post-contrast CT image in a cat with HS. In this instance the dorsoventral dimension
(height) of the enlarged pituitary was 6mm.
doi:10.1371/journal.pone.0127794.g001
Hypersomatotropism-Induced Diabetes Mellitus in the Cat
PLOS ONE | DOI:10.1371/journal.pone.0127794 May 29, 2015 6 / 18
these findings is depicted in Fig 2. This calculated positive predictive value for serum IGF-1
concentration> 1000 ng/ml therefore suggests the overall proportion of HS-induced DM cats
in the greater studied population of 1221 diabetic cats to be 24.8% (95% CI: 21.2–28.6%).
Additionally, 11 of 372 diabetic cats (3.0%) with an IGF-1> 500 ng/ml, though<1000 ng/ml
were recruited to have a CT-study of their pituitary performed (median IGF-1: 795 ng/ml, range:
526–986 ng/ml). One of these 11 cats (9.1%) had a demonstrable pituitary enlargement on CT
imaging. This cat had the highest IGF-1 concentration, close to the 1000 ng/ml cut-off (986 ng/ml).
On the basis of these data, the negative predictive value of the employed<1000 ng/ml cut-off
value for the diagnosis of HS in the diabetic cat is 91% (95% CI: 74–100%).
Pituitary enlargement prevalence in middle-aged and older cats
Mean pituitary height in 62 consecutive CT studies of cats presented for imaging of the head,
though explicitly not the brain, was 3.1+/-0.4 mm (SD). Only one cat displayed an increased pi-
tuitary size, with a pituitary height of 4.2 mm. This suggests the prevalence of incidental pitui-
tary enlargement in older cats to be 1.6% (95% CI: 0–4.7%).
Fig 2. Overview of the screening results. In total 1221 cats with diabetes mellitus were screened for HS; the results are summarised in this figure. IGF-1:
insulin-like growth factor-1; CT: computed tomography; MRI: magnetic resonance imaging; HS: hypersomatotropism; n: number of animals; PME: post-
mortem evaluation.
doi:10.1371/journal.pone.0127794.g002
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Clinical presentation of confirmed hypersomatotropism-induced DM
cases
The clinical details (clinical signs reported by cat owner and Veterinary Endocrinology Clinic
clinicians, including physical examination abnormalities suggestive of HS) of the 60 cats with
confirmed HS are summarised in Table 2. Most cats demonstrated signs compatible with dia-
betes mellitus, including polyuria, polydipsia and polyphagia. Phenotypical abnormalities his-
torically associated with feline HS and which form part of the clinical syndrome of acromegaly,
including prognathia inferior (protrusion of the mandible), weight gain, abdominal organome-
galy, broadening of paws (so-called clubbed paws) and face were present in only a minority of
cases. Examples of some of the obvious phenotypical changes encountered in a minority of cats
are shown in Figs 3–6. Compared to a diabetic control group without HS (based on normal
serum IGF-1), the following clinical features were statistically overrepresented in the HS group:
extreme polyphagia (p = 0.031), respiratory stridor/ snoring (p = 0.025) and broad facial fea-
tures (p<0.001), though only the latter feature proved significant after post hoc Bonferroni cor-
rection (Table 2).
Necropsy
Macroscopic and microscopic necropsy of the pituitary was performed in 12 of 319 cases of
suspect and/or confirmed HS-induced DM (3.8%), 11 of which underwent the above ante-
Table 2. Table depicting the clinical signs displayed by the diabetic cats in the group with confirmed HS, compared to a group of cats newly diag-
nosed with primary diabetes mellitus (non-acromegalic).
n = 60 Number of diabetic cats with confirmed
hypersomatotropism in which this was
present (percentage) n = 60
Number of diabetic cats without
HS in which this was present
(percentage) n = 20
Fischer’s exact test result
comparing the frequency
clinical sign (p = value)
Polyuria 52 (87%) 15 (75%) 0.29
Polydipsia 52 (87%) 17 (85%) 1.0
Polyphagia 45 (75%)Of which extreme: 12 (20%) 11 (55%) Of which extreme: 0
(0%)
0.100.031
Weight loss 25 (42%) 12 (60%) 0.20
Weight gain 10 (17%) 0 (0%) 0.059
Respiratory stridor /
‘snoring’
23 (38%) 2 (10%) 0.025
CNS signs (excluding
lethargy)
1 (1.7%) 0 (0%) 1.0
Lethargy 15 (25%) 7 (35%) 0.40
Stiffness / mobility
problems
6 (10%) 2 (10%) 1.0
Abdominal organomegaly
(renomegaly and/or
hepatomegaly
24 (40%) 5 (25%) 0.29
Prognathia inferior (Fig 4) 11 (18%) 2 (10%) 0.50
Clubbed paw appearance
(Fig 5)
8 (13%) 0 (0%) 0.19
Broad facial features (Fig 6) 22 (37%) 0 (0%) <0.001
Heart murmur 11 (18%) 4 (20%) 1.0
Plantegrade stance 2 (3%) 2 (10%) 0.26
In bold: significant p-value, not corrected for multiple comparisons; in bold and underlined: significant p-value after Bonferroni post-hoc correction for
multiple comparisons.
doi:10.1371/journal.pone.0127794.t002
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mortem intracranial imaging (Figs 7 and 8). HS could be convincingly confirmed in all 11 of
these latter cases on the basis of visualisation of acidophil hyperplasia (n = 4 of which one was
previously described [12]), adenoma (n = 6 of which 2 were previously described [12], Fig 8) or
adenocarcinoma (n = 1). The pituitary appeared normal on histopathology in one case with
IGF-1> 1000 ng/ml without prior intra-cranial imaging (this case was previously described as
part of the initial pilot study [12].
Discussion
It has been common practice to automatically suspect a cat with DM to be suffering from a
form of diabetes akin to human type 2 DM. The current study suggests that this is an oversim-
plification. Approximately one in four of assessed diabetic cats were found to be suffering from
HS-induced DM, which has a distinctly different aetiopathogenesis. HS therefore seems more
common in the cat with DM, compared to humans, though its prevalence among humans with
DM and glucose intolerance is similarly thought to be underestimated [18,19]. This is in line
with the results of a small pilot study the authors previously performed using the same method-
ology [12]. In light of this high prevalence and the demonstrated lack of ease of phenotypic rec-
ognition of HS in the diabetic cat, it is recommended that any future study using spontaneous
feline DM as a comparative model for human type 2 DM should consider screening for the dis-
ease. The same advice seems appropriate for veterinarians trying to manage DM in cats, given
the significant clinical consequences of its presence. Indeed, should the HS be diagnosed and
treated, most cats will enter a state of diabetic remission [16]. If the HS remains undiagnosed,
these diabetic cats tend to be difficult to regulate glycaemically. Given the financial limitations
in veterinary medicine, lack of prompt glycaemic control often results in euthanasia. If kept
alive, acromegalic cats will, in the long-term, suffer from other growth hormone-induced nega-
tive sequelae, as well as pituitary tumour induced central nervous signs [16].
Fig 3. Example of a cat before and after onset of HS-induced changes. Photo a was taken in 2009 and photo b after onset of HS-induced changes in
2012. HS-induced broad facial features are evident in the later picture.
doi:10.1371/journal.pone.0127794.g003
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In line with Melmed’s [18] and Rosario’s [19] findings in man, the current study also shows
that the measurement of total serum IGF-1 can be useful for the purpose of screening diabetic
Fig 4. Paws of an overtly acromegalic cat. This figure shows a cat with confirmed acromegaly
demonstrating so-called clubbed paws; enlargement of the paws due to acromegaly.
doi:10.1371/journal.pone.0127794.g004
Hypersomatotropism-Induced Diabetes Mellitus in the Cat
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cats for acromegaly, given its positive predictive value of 95% at a cut-off of 1000 ng/ml. The
negative predictive value was estimated to be 91% at this same cut-off. Admittedly, the one
case that proved to have a pituitary enlargement despite an IGF-1<1000 ng/ml had an IGF-1
very close to this cut-off (986 ng/ml). Pituitary enlargement appeared to be rare in the general
cat population (1.6%) on the basis of CT-evaluation of cats presented for other reasons than pi-
tuitary assessment. This further suggests that the calculated positive predictive value of an IGF-
1> 1000 ng/ml is accurate and unlikely an overestimation due to misclassification of inciden-
tal or non-functional pituitary enlargements.
It is recognised that circulating IGF-1 concentration can be influenced by various parame-
ters. For example, portal insulin is required for hepatic IGF-1 production. Since, in parallel
with people suffering from DM, endogenous insulin concentrations can be low in feline DM, a
low IGF-1 reading could be obtained when sampling takes place prior to initiation of exoge-
nous insulin treatment despite the presence of excess growth hormone due to acromegaly [16,
20]. For this reason, the current estimation of the prevalence of HS using IGF-1 as a screening
test could represent an underestimation. Duration of exogenous insulin administration has
been shown to affect circulating total IGF-1 concentrations [21–23]. The absence of a differ-
ence in duration of exogenous insulin administration between the> and< 1000 ng/ml IGF-1
groups, suggests that this factor did not pose a confounding factor that likely could have influ-
enced the current study’s main findings. Furthermore, the calculated Pearson correlation coef-
ficients suggested that in the studied population, any influence of duration of insulin
administration on IGF-1 concentrations to be rather small.”
Alternatively, reasons also exist why the current prevalence figure could be an overestima-
tion. These include the fact that recruitment of diabetic cat samples was driven by the fact that
veterinarians could obtain a free fructosamine evaluation as a measure of the cat’s glycaemic
control; the excess serum of these samples was used to determine IGF-1. Measuring fructosa-
mine is a common practice in both stable and unstable diabetics in veterinary medicine, though
this might have been of added interest in those cases whose DM proved more difficult to con-
trol. Acromegalic diabetic cats can prove more difficult to control from a DM point of view
[11] and samples of these cats could therefore have been preferentially sent in. Nevertheless,
the wide range of fructosamine concentrations in both the IGF-1<1000 ng/ml and the IGF-
Fig 5. Example of prognathia inferior. This figure shows a cat with confirmed acromegaly demonstrating prognathia inferior (a), including a sagittal CT view
of the cat’s head illustrating this conformational change further (b).
doi:10.1371/journal.pone.0127794.g005
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1>1000 ng/ml group suggests that overall a population with a mix of stable and unstable dia-
betic control was sampled. Finally, in the world of veterinary medicine, it would have been
near impossible to test the unprecedented number of diabetic cat samples assessed in the cur-
rent study without having provided an incentive related to the cats’ diabetic management. Pitu-
itary imaging proved useful in the assessed cases, although, in parallel with the situation in
Fig 6. Radiograph of the chest and abdomen of an overtly acromegalic cat. Cranial abdominal organomegaly was demonstrated by this radiographic
view of the chest and abdomen of a diabetic cat subsequently diagnosed with HS.
doi:10.1371/journal.pone.0127794.g006
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humans, both CT and MRI failed to detect a minority of cases due to the presence of only
microscopic changes.
In people the gold standard diagnosis of acromegaly involves performing a GH suppression
test through intravenous administration of glucose [18]. This suppression test has currently
not been validated for use in the cat and might not prove useful, since previously no suppres-
sion was shown to occur in four healthy cats [24]; further assessment of this test is currently
hampered by the absence of a commercially available feline GH assay. Human GH assays can-
not be used given the great inter-species heterogeneity of this hormone. Instead, therefore,
serum IGF-1 was used, which has been proven to be a relatively accurate diagnostic tool for es-
tablishing the presence of acromegaly both in humans [18,19] and the cat [16].
Interestingly, only a small proportion (24%) of clinicians submitting samples of cats which
subsequently proved to be at high risk of having acromegaly (IGF-1> 1000 ng/ml), reported
they strongly suspected acromegaly to be present on the basis of the clinical picture. This is
likely linked to the fact that acromegaly, like in humans [25], is a gradually progressive disease
in cats. The occurrence of DM often precedes the soft tissue and bony changes classically asso-
ciated with the disease in cats and diabetic signs are more acute in onset, as well as easier to
Fig 7. Microscopic image of the anterior pituitary of a diabetic cat with confirmed HS. A clear predominance of acidophils is apparent in the sections of
the pars distalis of the anterior pituitary (H&E staining; main image: objective 100x; inset: objective: 400x)
doi:10.1371/journal.pone.0127794.g007
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Fig 8. Macroscopic necropsy picture of the brain of a diabetic cat with confirmed HS. This picture shows the ventral aspect of the brain of a cat with HS
as it was removed from the cranial cavity and a clearly enlarged pituitary falling out of the sella turcica (cranium is held upside down; white arrow: pituitary
gland; yellow arrow: pituitary stalk; red arrow: cerebrum). Histopathology confirmed the presence of an acidophilic macroadenoma.
doi:10.1371/journal.pone.0127794.g008
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spot for cat owners. This implies that an acromegalic diabetic cat can easily be mistaken for a
non-acromegalic diabetic cat when only judging the phenotype. This is further demonstrated
in the current study, with only 40% of confirmed acromegalic cats displaying abdominal orga-
nomegaly, 18% showing prognathia inferior, 13% “clubbed paws” and 37% broad facial fea-
tures (of which only the latter proved statistically significantly increased in prevalence
compared to a diabetic control group). The occurrence of respiratory stridor / snoring in cats
with HS likely reflects reduced diameter of the nasopharynx, which occurs apparently as a re-
sult of thickening of soft tissues of the head [26].
The low prevalence of phenotypical changes suggestive of GH excess is likely also due to the
study design. The proactive screening approach adopted in the current study with as only re-
quirement presence of DM, likely resulted in acromegalic cases being diagnosed early on in the
disease process with little time having passed for GH and IGF-1 to exert their anabolic and cat-
abolic effects. In cats, additional difficulties recognising signs of acromegaly may occur because
of facial hair and the tendency for owners to examine their pet’s face infrequently. A recent
study included examples of 3-dimensional surface-rendered CT images, which display the
skin surface without hair, which enables a truer view of the surface contours. Even so, distin-
guishing affected and unaffected cats on the basis of their facial features is difficult [26].
A lack of awareness among both veterinary and medical professionals could further enhance
any underdiagnosis.
The current study also emphasises that the acromegalic cat could prove useful as a sponta-
neous model for the human form of the disease, especially given the fact that several factors are
shared by both species. These include: a shared environment, a pituitary acidophilic adenoma
as the most common cause of the growth hormone hypersecretion and, ultimately, occurrence
of similar physical changes in chronic cases, including prognathia inferior, broad facial fea-
tures, abdominal organomegaly, cardiomegaly and arthropathy. The prevalence of acromegaly
in the human population is relatively low, with estimates stated to be in the region of 40–128
cases/1,000,000 population [27, 28]. As a consequence, basic and clinical acromegaly research
suffers somehow from relatively slow recruitment of patients as well as biological samples. On
the other hand, with a prevalence of 26.1% among diabetic cats and an estimated prevalence of
diabetes of 1 in 200 cats in the UK [1] up to one and a half in 200 in the United States [3], the
overall estimated prevalence of acromegaly in the domestic cat could be significantly higher
than in the human population. The potential of feline acromegaly providing novel angles to
comparative acromegaly research was demonstrated in a recent study looking into the relation-
ship between environmental toxin exposure and occurrence of endocrinopathies, using the
acromegalic cat as a spontaneous model for the human disease. The study found that higher
levels of organohalogenated chemicals, which can be found in any household and can induce
pituitary oncogenesis, were present in the plasma of acromegalic household cats [4]. Addition-
ally, at least as interesting would be the study of those factors that are different in both species.
Particularly the seemingly lower prevalence of DM in man springs to mind. The prevalence of
DM among those suffering from acromegaly varies according to the study examined, though
seems broadly in the range of 19–56% [18,19]. This variation is likely due to the difference in
the studied populations, including ethnicity [18]. Higher GH concentrations, increasing age
and longer disease duration significantly predicted the tendency of developing symptomatic di-
abetes mellitus in humans [29,30]. The seemingly stronger association between acromegaly
and diabetes in the cat could therefore be due to the fact that acromegalic cats only get pre-
sented to a veterinary practice at a late stage in the disease process. What would argue against
that, however, would be the relatively low prevalence of phenotypical signs the diabetic acro-
megalic cats present with. Additionally, many acromegalic cats once effectively treated for the
acromegaly, will go into diabetic remission, possibly suggesting their endocrine pancreas has
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not yet been subjected to overly long periods of the insulin resistance associated with acromeg-
aly, leading to beta-cell exhaustion [16]. Interestingly, currently no case report exists in the lit-
erature of a non-diabetic acromegalic cat. In light of the above, there remains margin for yet to
be identified processes to be at work, explaining this higher prevalence of DM among feline ac-
romegalics. This encountered stronger association between feline acromegaly and feline DM,
compared to the human equivalents, could harbour novel information with regards to our un-
derstanding of the interaction between growth hormone, beta-cell dysfunction and
insulin resistance.
It could be argued that the DM was in fact a co-morbidity of the patients who happened to
also be diagnosed with acromegaly. Nevertheless, the authors deem it more likely that the DM
seen in these cats was induced by acromegaly. This is substantiated by the fact that the DM
often disappears if the acromegaly is effectively treated through hypophysectomy, radiotherapy
or somatostatin treatment [16, 31, 32, 33]. Furthermore, the diabetes-type that the acromegalic
cats suffer from seems to be more insulin-resistant than non-acromegalic diabetic cats, as illus-
trated by the significantly higher exogenous insulin requirements among acromegalic cats
found in this study.
Interestingly, although most cases submitted for post mortem showed evidence of an acido-
philic adenoma, 4/11 post mortem cases with confirmed acromegaly demonstrated acidophilic
hyperplasia. The distinction between hyperplasia and micro-adenoma can be arbitrary on mi-
croscopic examination of endocrine tissues and a continuum may exist between the two pro-
cesses [34]. Excess production of growth hormone–releasing hormone has been rarely
described to result in somatotroph hyperplasia and acromegaly [35]. Both central hypothalam-
ic tumours (usually gangliocytomas) and peripheral neuroendocrine tumours could secrete
growth hormone–releasing hormone (GHRH), inducing somatotroph proliferation (and very
rarely, the formation of an adenoma), with resultant elevations in levels of growth hormone
and IGF-I [18]. Evidence of neuroendocrine tumours or a hypothalamic lesion were not de-
tected during the thorough necropsies, despite macro- and microscopic evaluation of a wide
range of tissues (including hypothalamus and pancreas). An alternative explanation could lay
in the fact that microscopic classification and differentiation between adenoma and hyperplasia
remains notoriously challenging. Assessment of clonality of cells, as well as evaluation of circu-
lating GHRH concentrations might have helped, all of which are unfortunately not currently
available for the domestic cat.
Conclusions
The current study suggests that HS caused by a pituitary adenoma or hyperplasia is common
in the domestic cat with DM and explains the presence of DM in approximately 1 in 4 cats.
Cats with HS often display an unremarkable phenotype, indistinguishable from cats with pri-
mary (type 2) DM. The current data therefore provide a warning for researchers and veterinar-
ians working with the spontaneously diabetic cat to consider routinely screening such cats for
the presence of HS-induced DM; serum IGF-1 was confirmed to be a relatively good tool for
this. The encountered high prevalence and similarities between feline and human acromegaly
emphasise great opportunities exist for valuable comparative acromegaly research benefiting
all species suffering from this condition, including man.
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